Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company pioneering gene therapies and regenerative approaches for heart disease. This news hub provides investors and medical professionals with official updates on clinical developments, financial disclosures, and scientific advancements.
Access real-time updates on TNYA's investigational programs targeting genetic cardiomyopathies through AAV-based gene delivery and cellular regeneration technologies. Our curated feed includes earnings reports, FDA submissions, partnership announcements, and peer-reviewed research findings.
Key coverage areas span Phase 1/2 trial results for MYBPC3-associated hypertrophic cardiomyopathy therapies, manufacturing facility expansions, intellectual property milestones, and presentations at major cardiology conferences. Bookmark this page for verified updates on Tenaya's progress in developing potentially curative cardiac treatments.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company focused on therapies for heart disease, will present at the Piper Sandler 34th Annual Healthcare Conference in New York from November 29 to December 1, 2022. The company will participate in a panel discussion titled 'Heart to Heart with CV Players to Discuss 2023 Outlook' on November 29 at 2:30 p.m. ET and a fireside chat on November 30 at 8:30 a.m. ET. A webcast of the event can be accessed on Tenaya’s website, with a replay available for 30 days after.
Tenaya Therapeutics, Inc. (TNYA) announced a public offering of 22,613,307 shares at $2.60 each, raising approximately $75 million, with a 30-day option for underwriters to purchase an additional 4,327,500 shares. The offering includes pre-funded warrants for 6,236,693 shares at $2.599. The transaction, managed by Morgan Stanley and Piper Sandler, is set to close on or about November 21, 2022. Proceeds are intended to support the development of therapies for heart disease. However, investors should be aware of potential dilution from the offering.
Tenaya Therapeutics (TNYA) plans to offer $75 million in common stock through an underwritten public offering, along with the option for an additional $11.25 million. The offering will be managed by Morgan Stanley and Piper Sandler, with pre-funded warrants also available. The proceeds are intended for curative therapies targeting heart disease. This offering is contingent on market conditions, and there's no guarantee on its completion or terms. Full details will be provided in a prospectus supplement filed with the SEC.
Tenaya Therapeutics (TNYA) has extended its cash runway to mid-2024, concluding Q3 2022 with $149.5 million in cash and equivalents. The company initiated dosing for its Phase 1 clinical trial of TN-301, with results anticipated in 2023. Tenaya also plans to submit an Investigational New Drug application for TN-201 by year-end 2022 and received a patent for TN-201, expiring no earlier than 2041. R&D expenses totaled $23.8 million, with a net loss of $30.7 million, or $0.74 per share.
Tenaya Therapeutics (NASDAQ: TNYA) announced participation in the American Heart Association Scientific Sessions on November 5-7, 2022. The company will present research demonstrating the efficacy of its HDAC6 inhibitor TN-301 in treating heart failure with preserved ejection fraction (HFpEF). The study compares TN-301 to empagliflozin, revealing comparable efficacy in a mouse model. This highlights TN-301's potential as a first-in-class treatment targeting HFpEF, a condition affecting 50% of heart failure patients.
Tenaya Therapeutics (NASDAQ: TNYA) is set to present preclinical data for its gene therapy candidate, TN-201, at the inaugural Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 30, 2022. The presentation will focus on MYBPC3 gene mutations, a leading cause of hypertrophic cardiomyopathy (HCM), responsible for ~20% of cases. The data indicates potential for TN-201 to reverse cardiac dysfunction. Tenaya aims to submit an Investigational New Drug application for TN-201 in late 2022.
Tenaya Therapeutics, a clinical-stage biotechnology company focused on heart disease, announced CEO Faraz Ali's upcoming participation in two key conferences. He will engage in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022, at 11:00 a.m. ET. Additionally, Ali will present at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa on October 11, 2022, at 11:45 a.m. PT, followed by a panel discussion on October 13, 2022. Webcasts will be available on Tenaya's website for those unable to attend.
Tenaya Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, featuring a fireside chat at 3:30 p.m. ET. The second is the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, where the company will present at 3:00 p.m. ET. Webcasts of both events will be available on Tenaya's website for 30 days post-conference.
Tenaya Therapeutics (NASDAQ: TNYA) announced the FDA's clearance of its Investigational New Drug (IND) application for TN-301, its small molecule inhibitor targeting heart failure with preserved ejection fraction (HFpEF). This marks a significant step as Tenaya begins its first-in-human Phase 1 clinical trial in healthy adults. HFpEF affects over three million people in the U.S., with limited treatment options available. The trial will evaluate the safety and tolerability of TN-301, paving the way for potential therapeutic advancements in heart disease.
FAQ
What is the current stock price of Tenaya Therapeutics (TNYA)?
What is the market cap of Tenaya Therapeutics (TNYA)?
